应用GSI药物阻断Notch-1通路对骨肉瘤小鼠模型肿瘤生长及血管形成的影响Effect of Notchl channel blockers GSI in inhibited tumor growth osteosarcoma model on cytokine secretion: an animal experimental research
侯晓;李纯璞;郭冬梅;倪梅;陈丽;程雪梅;张开刚;
摘要(Abstract):
[目的]研究Notch-1通道阻断剂γ分泌酶抑制剂(gamma-secretase inhibitor,GSI)在抑制骨肉瘤小鼠模型中肿瘤增长以及其抑制肿瘤血管生成作用,进而探讨Notch-1信号通路在小鼠骨肉瘤模型中的作用及其作用机制。[方法]建立人骨肉瘤荷瘤SCID小鼠模型,将荷瘤成功后小鼠随机分为三组,实验组肿瘤内注射Notch通路阻断药物GSI,对照组注射PBS和DMSO。研究各组小鼠生物学指标、肿瘤增长变化及肿瘤组织检测微血管密度(microvessel density,MVD)的表达情况与差异。[结果]处死小鼠测量瘤体,同对照组相比,GSI治疗组小鼠的生物学指标明显较好,其小鼠的体重、饮食、睡眠、运动情况、精神状态、对刺激的反应及小鼠的皮毛光泽度等优于对照组,其皮下肿瘤体积明显较小,实验组平均体积为(196.3 mm3)较DMSO对照组平均体积(650.3 mm3)及PBS对照组平均体积(694.6 mm3)明显缩小,差别具有统计学意义,P<0.01。实验组及对照组内瘤体切片内血管均见不同程度的CD31表达,其表达于血管内皮细胞内,与对照组相比实验组CD31表达均明显降低,实验组及PBS、DMSO对照组CD31平均秩次分别为4.03、28.9和32.5,P<0.05,差异具有统计学意义。[结论](1)证实GSI可抑制SCID小鼠骨肉瘤动物模型肿瘤的生长;(2)GSI对SCID小鼠骨肉瘤动物模型的治疗作用可通过抑制Notch通路进而干预肿瘤血管形成来实现;(3)应用GSI药物阻断Notch信号通路有望成为骨肉瘤抗肿瘤治疗的新方法。
关键词(KeyWords): 骨肉瘤;Notch信号转导通路;血管生成;γ-分泌酶抑制剂
基金项目(Foundation): 山东省自然科学基金项目(编号:ZR2012HL38);; 山东省优秀中青年科学家科研奖励基金项目(编号:BS2013SF030)
作者(Author): 侯晓;李纯璞;郭冬梅;倪梅;陈丽;程雪梅;张开刚;
Email:
DOI:
参考文献(References):
- [1]Petrilli AS,de Camargo B,Filho VO,et al.Results of the brazilian osteosarcoma treatment group studies III and IV:prognostic factors and impact on survival[J].J Clin Oncol,2006,24(7):1161-1168.
- [2]Daw NC,Chou AJ,Jaffe N,et al.Recurrent osteosarcoma with a single pulmonary metastasis:a multi-institutional review[J].Br J Cancer,2015,112(2):278-282.
- [3]Bielack SS,Smeland S,Whelan JS,et al.Methotrexate,doxorubicin,and cisplatin(MAP)plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP:first results of the EURAMOS-1 good response randomized controlled trial[J].J Clin Oncol,2013,31(18):LBA10504.
- [4]Hattinger CM,Fanelli M,Tavanti E,et al.Advances in emerging drugs for osteosarcoma.[J].Expert Opin Emerg Drugs,2015,28(1):1-20.
- [5]赵海恩,赵新文,周勇,等.骨肉瘤转移的相关分子及临床应用研究进展[J].中国矫形外科杂志,2014,22(4):434-440.
- [6]何博,常彬,李锋.骨肉瘤转移的分子研究进展[J].中国矫形外科杂志,2013,21(2):159-162.
- [7]Perissinotto E,Cavalloni G,Leone F,et al.Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression[J].Clin Cancer Res,2005,11(1):490-497.
- [8]Poncelet C,Fauvet R,Feldmann G,et al.Prognostic value of von Willebrand factor,CD34,CD31,and vascular endothelial growth factor expression in women with uterine leiomyosarcomas[J].J Surg Oncol,2004,86(2):84-90.
- [9]Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180.
- [10]Grishina IB.Mini-review:does Notch promote or suppress cancer?New findings and old controversies[J].Am J Clin Exp Urol,2015,3(1):24-27.
- [11]Huntzicker EG,Htzel K,Choy L,et al.Differential effects of targeting Notch receptors in a mouse model of liver cancer[J].Hepatology,2015,61(3):942-952.
- [12]Zhang P,Yang Y,Zweidler-Mc Kay PA,et al.Critical role of notch signaling in osteosarcoma invasion and metastasis[J].Clin Cancer Res,2008,14(10):2962-2969.
- [13]Guruharsha KG,Kankel MW,Artavanis-Tsakonas S.The Notch signalling system:recent insights into the complexity of a conserved pathway[J].Nat Rev Genet,2012,13(9):654-666.
- [14]刘兆国,范方田,赵林钢,等.肿瘤血管生成新靶点LRG1研究进展[J].中国药理学通报,2014,30(1):6-9.
- [15]Yan B,Liu L,Zhao Y,et al.Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells[J].World J Gastroenterol,2014,20(36):13105-13118.